Main Research and Development Centers
Each of our R&D centers specializes in a different area of scientific exploration. We have several major campuses located throughout the U.S. and U.K.
Andover, Massachusetts
A 70-acre site that combines state-of-the-art R&D facilities with flexible, multi-product manufacturing capabilities
Cambridge, Massachusetts
Located in Kendall Square, our Cambridge site interlaces Pfizer’s R&D capability with the densest biomedical community in the world
Groton, Connecticut
Where nearly every one of our products are, in part, developed
La Jolla, California
With more than 500,000 square feet of state-of-the-art facilities, this is where our scientists discover and develop cutting-edge cancer therapies using advanced laboratories and equipment.
Pearl River, New York
The primary location for our company’s global Vaccine Research and Development work
Sandwich, UK
Home of the Pharmaceutical Sciences and Global Regulatory Affairs groups
St. Louis, MO
A 300,000 sq. ft. facility producing innovative emergency care products that serve unique needs during severe medical crises

Clinical Trials
Learn more about the process of joining a clinical trial and find a trial near you.
Go to Pfizer Clinical Trials Site DetailsRelated Articles
Science & Innovation
Spotting the Signs of ATTR-CM: Latest Data Reveals Opportunities for More Timely Detection
For many people living with transthyretin amyloid cardiomyopathy (ATTR‑CM) – a rare and underdiagnosed cause of heart failure – receiving an accurate diagnosis can be a long and uncertain journey.
Science & Innovation
As Colorectal Cancer Rises in Younger Populations, Research and Education is More Important than Ever
At one time, colorectal cancer was a disease associated with older adults. Now, it’s considered the most deadly cancer in people younger than 50.
Real People
One Pediatric Gastroenterologist’s Mission to Expand Pediatric Treatment Options
Dr. Nicole Kulisek shares her path from pediatric gastroenterologist to US Medical Affairs leader at Pfizer.










